Evidence map›Paper›PMID 37381013›Full record

SynthesisMalaria journal2023

Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models.

Xiaoyan Yin, Ying Li, Wilhelmina Bagchus, Özkan Yalkinoglu, Deon Bezuidenhout, Aliona Tappert, James McCarthy, Louise Marquart, Claude Oeuvray

Abstract readMeta-Analysis
In one paragraph

Synthesis in Malaria journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaoyan YinEMD Serono Research & Development Institute, Inc. (an Affiliate of Merck KGaA), 45 Middlesex Turnpike, Billerica, MA, 01821, USA. xiaoyan.a.yin@emdserono.com.
Ying LiEMD Serono Research & Development Institute, Inc. (an Affiliate of Merck KGaA), 45 Middlesex Turnpike, Billerica, MA, 01821, USA.
Wilhelmina BagchusWMB: Merck Serono S.A (an Affiliate of Merck KGaA), Lausanne, Switzerland.
Özkan YalkinogluMerck KGaA, Darmstadt, Germany.
Deon BezuidenhoutWMB: Merck Serono S.A (an Affiliate of Merck KGaA), Lausanne, Switzerland.
Aliona TappertMerck KGaA, Darmstadt, Germany.
James McCarthyQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Louise Marquart *QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Claude Oeuvray *The Global Health Institute of Merck (an Affiliate of Merck KGaA), Eysins, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvaluation of parasite clearance patterns in experimental human infection trials helps increase understanding of drug action. In a previously reported phase Ib trial of a new investigational anti-malarial drug M5717, parasite clearance showed a biphasic linear pattern: slow removal phase with a near flat clearance rate followed by a fast clearance phase with a steep slope. In this study three statistical approaches were implemented and compared to estimate the parasite clearance rate for each phase and the time point corresponding to the change of clearance rates (changepoint between the two phases).

methodsData using three M5717 doses 150 mg (n = 6), 400 mg (n = 8), 800 mg (n = 8) were used to estimate biphasic clearance rates. Three models were investigated: firstly, segmented mixed models with estimated changepoint-models with/without random effects in various parameters were compared. Secondly, a segmented mixed model using grid search-this method is similar to the first except that changepoints were not estimated, instead they were selected based on model fit from given candidate values. Thirdly, a two-stage approach whereby a segmented regression model fit to each participant followed by a meta-analysis method. Hourly rate of parasite clearance (HRPC) interpreted as the percentage of parasites removed each hour was calculated.

resultsThe three models generated similar results. Using segmented mixed models, the estimated changepoints after treatment in hours (95% CI) were: 150 mg: 33.9 (28.7, 39.1); 400 mg: 57.4 (52.5, 62.4); and 800 mg: 52.8 (47.4, 58.1). For all three treatment groups, there was nearly no clearance before the changepoints, but rapid clearance in the second phase (HRPC [95% CI]): 150 mg: 16.8% (14.3, 19.1%); 400 mg: 18.6% (16.0, 21.1%); and 800 mg: 11.7% (9.3, 14.1%).

conclusionsAll three statistical approaches are effective tools to characterize the bi-phasic clearance of M5717 in the phase 1b experimental Plasmodium falciparum malaria human infection study. The statistical approaches produced similar results to estimate the two-phase clearance rates and the changepoint for each treatment dose of M5717. However, the segmented mixed model with random changepoints has several advantages: it is computationally efficient, provides precision for changepoint estimates and is robust concerning outlying datapoints or individuals.

Indexed as

AntimalarialsMalaria, FalciparumParasitesAnimalsHumansKineticsAntimalarialsMalariaParasite clearanceSegmented mixed model

Identifiers

PMID37381013
PMCPMC10303793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.